| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1005376332 |
| P356 | DOI | 10.1038/SJ.ONC.1210586 |
| P698 | PubMed publication ID | 17599054 |
| P5875 | ResearchGate publication ID | 6238635 |
| P50 | author | Nicola Curtin | Q68388645 |
| P2093 | author name string | C N Robson | |
| A C Rigas | |||
| P2860 | cites work | Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development | Q40651903 |
| Androgen stimulated cellular proliferation in the human prostate cancer cell line LNCaP is associated with reduced retinoblastoma protein expression | Q40762889 | ||
| Proliferation of cancer cells despite CDK2 inhibition. | Q44391102 | ||
| Cdc2-cyclin E complexes regulate the G1/S phase transition | Q46592665 | ||
| Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomas | Q70888925 | ||
| N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2 | Q24298676 | ||
| Expression profile of differentially-regulated genes during progression of androgen-independent growth in human prostate cancer cells | Q24300247 | ||
| Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles | Q27626674 | ||
| Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1 | Q28145116 | ||
| Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation | Q28609667 | ||
| New colorimetric cytotoxicity assay for anticancer-drug screening | Q29615418 | ||
| The development of androgen-independent prostate cancer | Q29615650 | ||
| Role of p27 in prostate carcinogenesis | Q33715175 | ||
| S and G2 phase roles for Cdk2 revealed by inducible expression of a dominant-negative mutant in human cells | Q33941051 | ||
| Bicalutamide functions as an androgen receptor antagonist by assembly of a transcriptionally inactive receptor | Q34128784 | ||
| Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity | Q34433798 | ||
| Dual mechanisms for the inhibition of E2F binding to RB by cyclin-dependent kinase-mediated RB phosphorylation | Q36573000 | ||
| Retinoblastoma tumor suppressor targets dNTP metabolism to regulate DNA replication | Q38363095 | ||
| Combined depletion of cell cycle and transcriptional cyclin-dependent kinase activities induces apoptosis in cancer cells | Q40230424 | ||
| Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment | Q40383746 | ||
| P433 | issue | 55 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 7611-7619 | |
| P577 | publication date | 2007-06-18 | |
| P1433 | published in | Oncogene | Q1568657 |
| P1476 | title | Therapeutic potential of CDK inhibitor NU2058 in androgen-independent prostate cancer | |
| P478 | volume | 26 |
| Q42006737 | A naturally derived small molecule disrupts ligand-dependent and ligand-independent androgen receptor signaling in human prostate cancer cells |
| Q35543453 | Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer cells |
| Q53302883 | Cell‐cycle regulators cdk2ap1 and bicalutamide suppress malignant biological interactions between prostate cancer and bone cells |
| Q28484264 | Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancer |
| Q52637922 | Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. |
| Q35722786 | Insights on Structural Characteristics and Ligand Binding Mechanisms of CDK2 |
| Q38895320 | Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells |
| Q62612784 | Molecular mechanism of the TP53-MDM2-AR-AKT signalling network regulation by USP12 |
| Q38812632 | Nutlin-3 inhibits androgen receptor-driven c-FLIP expression, resulting in apoptosis of prostate cancer cells. |
| Q39673124 | Preferential induction of G1 arrest in androgen-responsive human prostate cancer cells by androgen receptor signaling antagonists DL3 and antiandrogen bicalutamide |
| Q35082989 | Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence. |
| Q58572503 | Synthesis and pharmacological evaluation of novel epidermal growth factor receptor inhibitors against prostate tumor cells |
| Q38259961 | The androgen receptor controls expression of the cancer-associated sTn antigen and cell adhesion through induction of ST6GalNAc1 in prostate cancer. |
| Q39189709 | The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover. |
| Q55129906 | The novel anti-androgen candidate galeterone targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survival. |
| Q38407976 | Upregulated FGFR1 expression is associated with the transition of hormone-naive to castrate-resistant prostate cancer. |
Search more.